

## Director's Report on Developmental Progress Assessment

**Date of Visit:** 09-06-2023

**Child's Name:** Salma Ayman Ghannam

**Date of Birth:** 09-06-2023

**Gender:** Female

**Guardian:** Ayman

### Overview

Salma Ayman Ghannam was assessed at our center on 09 June 2023. The evaluation revealed **information-processing delays** and **global developmental delays**, which have resulted in **cognitive developmental-delay features** and **acquired features of autism**.

It is important to note that Salma **does not currently score as a case of autism**; however, the acquired features indicate the need for early intervention and close follow-up to prevent progression and support optimal development.

### Recommended Plan

#### 1) Development Protocol for Information Processing

- Begin the tailored development protocol for **4 months**.
- Reassess after 4 months—preferably **in person**—to establish a baseline and adjust the plan accordingly.
- Continue the intervention plan as guided by progress.
- **Follow-up with a neurologist** and obtain a **brain MRI** to better understand any underlying neurological factors that may contribute to her developmental profile.

#### 2) Main Recommended Analyses – Conducted through Neurazon (Canada)

##### Notes on External Testing:

The recommended tests are conducted through **Neurazon (Canada)**, a bioinformatics company partnered with certified laboratories worldwide. These tests are **external to our center**.

**Please note that they are recommendations and not obligatory**, and they are not performed directly by EICADD. Parents are encouraged to refer to the plan provided by Neurazon for further details.

### 3) Recommended Therapy

- **Rehabilitation Therapy:** Continue an intensive therapy schedule including:
  - 2 Speech-Therapy (ST) sessions per week
  - 2 Occupational-Therapy (OT) sessions per week
  - 2 Language-Therapy (LT) sessions per week

### Conclusion

Salma's developmental profile shows areas of concern that require close monitoring and proactive intervention. Early therapy, coupled with biomedical investigations and follow-up with a neurologist, will provide essential insights and improve the likelihood of favorable developmental outcomes.

### Disclaimer

This assessment is **not a final diagnosis** but a developmental evaluation based on current observations. Salma Ayman Ghannam is open to improvement, and the findings may change with progress and intervention. The recommended tests are external and provided through **Neurazon (Canada)**. These are suggestions, **not obligatory**, and are intended to support a deeper understanding of the child's developmental profile. Please refer to the plan provided by Neurazon for further information. These tests are not conducted directly through our center. This report remains **active for 4 months** from the date of assessment.

*This report is valid for 4 months from the date of assessment.*

### Signature:

EICADD Center

### Center's Leading Staff:

**Speech Therapist:** Ms. Amira Alomari

**Occupational Therapist:** Ms. Malak Jaber

**Psychologist and behaviour therapist:** Ms. Asmaa Alshanawi

**EICADD Center Director**

The signature of Dr. Noraldin Al-Harbi is written in black ink over a blue circular stamp. The stamp contains the EICADD logo and the text 'مركز التدخل المبكر للتوحد واضطرابات النمو Early Intervention Center for Autism and Developmental Disorders'. Below the signature, the name 'Dr. Noraldin Al-Harbi' is printed.